A Cohort Study to Assess the Impact of Pediatric Use of Proton Pump Inhibitors On the Risk of Community Acquired Infections. Data from a French General Practitioners and Pediatricians Longitudinal Patient Database

2017 ◽  
Vol 152 (5) ◽  
pp. S240
Author(s):  
Maxime Luu ◽  
Isabelle Le Ray ◽  
Alan N. Barkun ◽  
Laure Luu ◽  
Frederic Huet ◽  
...  
Keyword(s):  
Cohort Study ◽  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Patient Database ◽  
Pediatric Use ◽  
The Impact

scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

scholarly journals Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
General Practitioners ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Causal Relation ◽  
High Standard ◽  
Choosing Wisely ◽  
Royal Australian College ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of high/standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of high/standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of high/standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists

2017 ◽  
Vol 34 (4) ◽  
pp. 577-583 ◽  
Author(s):  
Eline Houben ◽  
Saga Johansson ◽  
Péter Nagy ◽  
Fernie J. A. Penning-van Beest ◽  
Ernst J. Kuipers ◽  
...  
Keyword(s):  
Cohort Study ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Observational Cohort Study ◽  
Receptor Antagonists ◽  
Safety Outcomes ◽  
Observational Cohort

Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study

2017 ◽  
Vol 33 (12) ◽  
pp. 2251-2259
Author(s):  
Ana Ruigómez ◽  
Leanne M. A. Kool-Houweling ◽  
Luis A. García Rodríguez ◽  
Fernie J. A. Penning-van Beest ◽  
Ron M. C. Herings
Keyword(s):  
Cohort Study ◽  
Children And Adolescents ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Observational Cohort Study ◽  
Receptor Antagonists ◽  
Observational Cohort

Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics

2017 ◽  
Vol 51 (10) ◽  
pp. 848-854 ◽  
Author(s):  
Paul O. Lewis ◽  
Timothy S. Lundberg ◽  
Jennifer L. Tharp ◽  
Clay W. Runnels
Keyword(s):  
Cohort Study ◽  
Clostridium Difficile ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clostridium Difficile Infection ◽  
Retrospective Cohort ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Order Sets ◽  
Global Strategies

Background: Proton pump inhibitors (PPIs) have been identified as a significant risk factor for the development of Clostridium difficile infection (CDI). Probiotics given concurrently with antibiotics have been shown to have a moderate impact on preventing CDI. Objective: To evaluate the effectiveness of hospital-wide interventions designed to reduce PPI use and increase probiotics and whether these interventions were associated with a change in the incidence of hospital onset (HO)-CDI. Methods: This retrospective cohort study compared 2 fiscal years: July 2013 to June 2014 (FY14) and July 2014 to June 2015 (FY15). In July of FY15, global educational initiatives were launched targeting PPIs. Additionally, a HO-CDI prevention bundle was added to antibiotic-containing order sets targeting probiotics. Overall PPI use, probiotic use, and incidence of HO-CDI were recorded and compared for each cohort. Charts were also reviewed for patients who developed HO-CDI for the presence and appropriateness of a PPI and presence of probiotics. Results: The interventions resulted in a decrease in PPI use by 14% or 96 doses/1000 patient days (TPD; P = 0.0002) and a reduction in IV PPI use by 31% or 71 doses/TPD ( P = 0.0008). Probiotic use increased by 130% or 126 doses/TPD ( P = 0.0006). The incidence of HO-CDI decreased by 20% or 0.1 cases/TPD ( P = 0.04). Conclusions: A collaborative, multifaceted educational initiative directed at highlighting the risks associated with PPI use was effective in reducing PPI prescribing. The implementation of a probiotic bundle added to antibiotic order sets was effective in increasing probiotic use. These interventions were associated with a decrease in incidence of HO-CDI.

scholarly journals Impact of NPS MedicineWise General Practitioner education programs and Choosing Wisely Australia recommendations on prescribing of Proton Pump Inhibitors in Australia

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
High Strength ◽  
Choosing Wisely ◽  
Education Programs ◽  
Time Series Analyses ◽  
Low Strength ◽  
Practitioner Education ◽  
The Impact ◽  
Pharmaceutical Benefits Scheme

Abstract Background This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods Time series analyses of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were National NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the RACGP. Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the expected dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016. Although the rate of high-strength PPI prescribing is declining, these formulations still constitute the majority of PPI use in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

Sign in / Sign up

Export Citation Format

Share Document